Investigation about treatment of midnight hypertension in diabetes

Investigation about treatment of midnight hypertension in diabetes - Investigation about treatment of midnight hypertension in diabetes

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002205

Enrollment

Registered

2009-09-15

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension in diabetes

Interventions

olmesartan 20 mg +amlodipine 5mg once daily olmesartan 20 mg + azelnidipine 16 mg once daily candesartan 8 mg or varsartan 80 mg + amlodipine 5mg once daily candesartan 8 mg or varsartan 80 mg + az

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: diabetes patient having midnight hypertension

Exclusion criteria

Exclusion criteria: 1) drug allergy to ARB or Ca antagonist 2) pregnant women or possible pregnant women 3) using anti-fugal drug or HIV protease inhibitor 4) bilateral renal artery stenosis or unilateral renal artery stenosis of remnant kidny

Design outcomes

Primary

Measure	Time frame
comparison of the anti-hypertensive effect through the 24 hrs	—

Secondary

Measure	Time frame
change in urinary albumin excretion ratio	—

Countries

Japan

Contacts

Public ContactKazuhiko sakaguchi

Department od Internal Medicine, Kobe University Graduate School of Medicine Division of diabetes, metabolism and Endocrinology

kzhkskgc@med.kobe-u.ac.jp078-382-5861

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026